Holen Sie sich die Stockscreener-App
35.72
0.22%
0.08
Vorhandelsmarkt:
36.48
0.76
+2.13%
Schlusskurs vom Vortag:
$35.64
Offen:
$35.41
24-Stunden-Volumen:
799.89K
Relative Volume:
0.44
Marktkapitalisierung:
$4.61B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-507.65M
KGV:
-7.7652
EPS:
-4.6
Netto-Cashflow:
$-616.24M
1W Leistung:
+1.25%
1M Leistung:
+8.67%
6M Leistung:
-58.77%
1J Leistung:
-57.50%
1-Tages-Spanne:
$35.25
$36.18
1-Wochen-Bereich:
$35.25
$37.95
52-Wochen-Spanne:
$27.66
$121.06
Vaxcyte Inc Stock (PCVX) Company Profile
Firmenname
Vaxcyte Inc
Sektor
Branche
Telefon
650-837-0111
Adresse
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Vergleichen Sie PCVX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
35.72 | 4.55B | 0 | -507.65M | -616.24M | -4.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Vaxcyte Inc Stock (PCVX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-20 | Eingeleitet | Goldman | Buy |
| 2023-12-07 | Eingeleitet | Mizuho | Buy |
| 2023-04-18 | Eingeleitet | TD Cowen | Outperform |
| 2023-01-03 | Bestätigt | Needham | Buy |
| 2022-12-15 | Eingeleitet | Guggenheim | Buy |
| 2022-11-17 | Eingeleitet | BTIG Research | Buy |
| 2021-12-29 | Fortgesetzt | Jefferies | Buy |
| 2021-06-24 | Fortgesetzt | Jefferies | Buy |
| 2020-07-07 | Eingeleitet | BofA Securities | Buy |
| 2020-07-07 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-07-07 | Eingeleitet | Needham | Buy |
Alle ansehen
Vaxcyte Inc Aktie (PCVX) Neueste Nachrichten
What drives Vaxcyte Inc. stock priceGame-changing capital returns - jammulinksnews.com
Is Vaxcyte Inc. a good long term investmentBreakout profit opportunities - Autocar Professional
What analysts say about Vaxcyte Inc. stockRemarkable growth - jammulinksnews.com
Vaxcyte Inc. Stock Analysis and ForecastExponential wealth increase - jammulinksnews.com
Mizuho Maintains an Overweight Rating on Vaxcyte (PCVX) - MSN
Nisa Investment Advisors LLC Buys 293 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) - Defense World
How the (PCVX) price action is used to our Advantage - news.stocktradersdaily.com
Vaxcyte’s High-Stakes Bet On Next-Gen Pneumonia Vaccines - Finimize
What makes Vaxcyte Inc. stock price move sharplyBreakout Momentum Stocks - beatles.ru
Why Vaxcyte Inc. stock attracts strong analyst attentionBig Profit Small Risk Alerts - Newser
How Vaxcyte Inc. stock performs during market volatilityRisk Adjusted Stock Signals - Newser
Teacher Retirement System of Texas Sells 2,779 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) - Defense World
Here’s Why Vaxcyte (PCVX) Sold Off in Q1 - Insider Monkey
(PCVX) Trading Advice - news.stocktradersdaily.com
Cantor Fitzgerald Maintains Overweight on Vaxcyte Amid Vaccine Development and ACIP Meeting - MSN
Vaxcyte (PCVX): Riding Passive Fund Winds to FDA Catalysts – A Tactical Play with Strategic Upside - AInvest
Vaxcyte, Inc.(NasdaqGS: PCVX) added to Russell 2500 Value Index - MarketScreener
Vaxcyte (PCVX): Riding Clinical Catalysts Against a Stormy Regulatory Tide - AInvest
Vaxcyte Holds Annual Stockholders Meeting on Governance - TipRanks
How To Trade (PCVX) - news.stocktradersdaily.com
Cantor Fitzgerald Estimates Vaxcyte FY2026 Earnings - Defense World
Transcript : Vaxcyte, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 01 - MarketScreener
Vaxcyte: Sentiment Is Pushing The Shares Down (NASDAQ:PCVX) - Seeking Alpha
Cantor Fitzgerald maintains Overweight on Vaxcyte shares By Investing.com - Investing.com Canada
Vaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Rating of “Buy” by Analysts - Defense World
(PCVX) Long Term Investment Analysis - news.stocktradersdaily.com
Head to Head Contrast: Vaxcyte (NASDAQ:PCVX) and Beam Therapeutics (NASDAQ:BEAM) - Defense World
Vaxcyte (VCYT) Jumps Over 4.5%: Is This Biotech Eyeing a Return Towards Its $121 High? - Daily Chhattisgarh News
Finanzdaten der Vaxcyte Inc-Aktie (PCVX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):